Literature DB >> 8635181

The drug-drug interaction effects of haloperidol on plasma carbamazepine levels.

K Iwahashi1, R Miyatake, H Suwaki, K Hosokawa, Y Ichikawa.   

Abstract

The metabolic interaction between carbamazepine (CBZ) and haloperidol (HP) was studied in Japanese schizophrenic patients treated with HP but not with CBZ and with both CBZ and HP. The serum CBZ concentrations in patients treated without HP were significantly decreased (p < 0.05), on average approximately 40%, as compared to those in patients treated with both CBZ and HP, whereas the serum HP concentrations in patients treated with both HP and CBZ were significantly decreased (p < 0.05), as compared to those in patients treated with HP but not with CBZ. The effect of HP, which prevents the serum CBZ level from decreasing, was shown in this study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8635181     DOI: 10.1097/00002826-199506000-00003

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  7 in total

1.  Pharmacokinetic interactions of Mentat with carbamazepine and phenytoin.

Authors:  M Tripathi; R Sundaram; M Rafiq; M V Venkataranganna; S Gopumadhavan; S K Mitra
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

Review 2.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.

Authors:  J J Miceli; R J Anziano; L Robarge; R A Hansen; A Laurent
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

Review 4.  Interactions between antiepileptic and antipsychotic drugs.

Authors:  Frank M C Besag; David Berry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid.

Authors:  M Ucar; M Neuvonen; H Luurila; R Dahlqvist; P J Neuvonen; T Mjörndal
Journal:  Eur J Clin Pharmacol       Date:  2003-12-23       Impact factor: 2.953

Review 6.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02

Review 7.  A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review.

Authors:  Yu-Jie Chiou; Yu Lee; Chin-Chuen Lin; Tiao-Lai Huang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.